Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)

Clinical trial NCT06984328 · TERMINATED

Trial details

NCT number: NCT06984328
Sponsor: Genmab
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Cutaneous Melanoma Relapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID)Metastatic Cutaneous Melanoma (Stage IV)

Start date: 2025-07-25
Primary completion: 2026-05-15
Enrollment: 1

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.